The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation. METHODS: In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety. RESULTS: Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). CONCLUSIONS: Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan was associated with a 13.6% risk of interstitial lung disease (ILD)/pneumonitis, fatal in 2.2% of cases, which needed appropriate and rapid diagnosis and treatment.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trastuzumab deruxtecan (DS-8201), an ADC composed of trastuzumab, a cleavable tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor, demonstrated a response rate of 60.6% (95% CI 53.4-68.0) and an unprecedented median PFS of 16.4 months (95% CI 12.7—not reached) in a phase II study of heavily pretreated patients (median six lines, range 2-27 lines, including trastuzumab and T-DM1).64”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., van de Vijver, M. J., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. O. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,190
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,163
Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009) · Clinical Medicine & Research · doi:10.3121/cmr.2009.825 · Cited by 1,023
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- 10.3121/cmr.2008.825 · DOI
- Modi S Tsurutani J Takahashi S et al. Safety and efficacy results from a phase 1 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2 expressing metastatic breast cancers. Presented at the 2017 San Antonio Breast Cancer Symposium San Antonio TX December 5–9 2017.
Cited by
Sorted by citations
Items 401–500 of 1,000
Biologic therapy for advanced breast cancer: recent advances and future directions
Tarantino, P., Morganti, S., & Curigliano, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1752176 · Cited by 38
Aoki, M., Iwasa, S., & Boku, N. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01164-x · Cited by 36
Targeting HER2 genomic alterations in non-small cell lung cancer
Zeng, J., Ma, W., Young, R. B., & Li, T. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.04.001 · Cited by 37
Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development
Singh, D., Dheer, D., Samykutty, A. K., & Shankar, R. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.006 · Cited by 35
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential
Ceci, C., Lacal, P. M., & Graziani, G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108106 · Cited by 36
Ma, W., Yang, Y., Liu, Z., Zhao, R., Wan, Q., Chen, X., Tang, B., Zhou, Y., & Lin, Y. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c07344 · Cited by 35
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
Noblejas‐López, M. D. M., Gandullo‐Sánchez, L., Galán‐Moya, E. M., López‐Rosa, R., Tébar-García, D., Nieto‐Jiménez, C., Sango, M. G., Burgos, M., Pandiella, A., & Ocaña, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105476 · Cited by 35
Masri, J. E., & Phadke, S. D. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000721 · Cited by 35
Li, J., Wang, Z. H., Chen, L., Zhang, W. J., Ma, L., Wu, J., Liu, G. Y., Hou, Y. F., Yu, K., Di, G., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.02.011 · Cited by 34
Antibody-drug conjugates in breast cancer: current evidence and future directions
Li, N., Yang, L., Zhao, Z., Du, T., Li, N., Tang, J., & Tang, J. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00632-9 · Cited by 38
Dahlgren, D., & Lennernäs, H. (2020) · Molecules · doi:10.3390/molecules25122861 · Cited by 34
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
Bartsch, R. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1792443 · Cited by 34
Awake breast cancer surgery: strategy in the beginning of COVID-19 emergency
Vanni, G., Pellicciaro, M., Materazzo, M., Dauri, M., D’Angelillo, R. M., BUONOMO, C., Majo, A. D., Pistolese, C. A., Portarena, I., Mauriello, A., et al. (2020) · Breast Cancer · doi:10.1007/s12282-020-01137-5 · Cited by 34
Zhou, Z., Liu, Y., Zhu, X., Tang, X., Wang, Y., Wang, J., Xu, C., Wang, D., Du, J., & Zhou, Q. (2020) · Genes · doi:10.3390/genes11101187 · Cited by 34
Schlam, I. M., Church, S., HETHER, T. D., Chaldekas, K. M., Hudson, B. M., White, A. M., Maisonet, E., Harris, B. T., & Swain, S. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03113-9 · Cited by 37
Recombinant immunotoxins development for HER2-based targeted cancer therapies
Mahmoudi, R., Dianat‐Moghadam, H., Poorebrahim, M., Siapoush, S., Poortahmasebi, V., Salahlou, R., & Rahmati, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02182-6 · Cited by 34
Azar, I. H., Alkassis, S., Fukui, J. A., Alsawah, F., Fedak, K., Hallak, M. N. A., Sukari, A. W., & Nagasaka, M. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s307324 · Cited by 37
Thill, M., Friedrich, M., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2021) · Breast Care · doi:10.1159/000516420 · Cited by 34
O'Brien, N. A., Huang, H., McDermott, M. S. J., Madrid, A. M., Luo, T., Ayala, R., Issakhanian, S., Gong, K. W., Lu, M., Zhang, J., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0847 · Cited by 34
The current management and biomarkers of immunotherapy in advanced gastric cancer
Chang, X., Ge, X., Zhang, Y., & Xue, X. (2022) · Medicine · doi:10.1097/md.0000000000029304 · Cited by 35
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Koirala, N., Dey, N., Aske, J. C., & De, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126547 · Cited by 35
Fu, Z., Liu, J., Li, S., Chen, S., & Zhang, Y. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101795 · Cited by 35
Self-citationAntibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Grinda, T., Rassy, E., & Pistilli, B. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01072-5 · Cited by 34
Sentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 34
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
DiPeri, T. P., Evans, K. W., Raso, M. G., Zhao, M., Rizvi, Y. Q., Zheng, X., Wang, B., Kirby, B. P., Kong, K., Kahle, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0103 · Cited by 35
Thill, M., Kolberg‐Liedtke, C., Albert, U., Banys-Paluchowski, M. J., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Ditsch, N., Fallenberg, E. M., et al. (2023) · Breast Care · doi:10.1159/000531579 · Cited by 34
Dannehl, D., Jakob, D., Mergel, F., Estler, A., Engler, T., Volmer, L., Frevert, M. L., Matovina, S., Englisch, A., Tegeler, C. M., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102995 · Cited by 33
Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies
Lai, Q., Wu, M., Wang, R., Lai, W., Tao, Y., Lu, Y., Wang, Y., Yu, L., Zhang, R., Peng, Y., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112364 · Cited by 33
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 33
Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target
Javaid, F., Pilotti, C., Camilli, C., Kallenberg, D. M., Bahou, C., Blackburn, J. W. D., Baker, J. R., Greenwood, J., Moss, S. E., & Chudasama, V. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00104c · Cited by 33
Spring, L. M., Clark, S. L., Li, T., Goel, S., Tayob, N., Viscosi, E., Abraham, E., Juric, D., Isakoff, S. J., Mayer, E. L., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00311-y · Cited by 34
Waliany, S., Caswell-Jin, J. L., Riaz, F., Myall, N. J., Zhu, H., Witteles, R. M., & Neal, J. W. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.007 · Cited by 33
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
Ascione, L., Crimini, E., Trapani, D., Marra, A., Criscitiello, C., & Curigliano, G. (2023) · The Oncologist · doi:10.1093/oncolo/oyad246 · Cited by 35
The History and Development of HER2 Inhibitors
Xia, X., Chen, G., Zhang, Y., & Xiong, H. (2023) · Pharmaceuticals · doi:10.3390/ph16101450 · Cited by 34
Chung, W., Huang, W.-L., Lee, C., Hsu, H., Huang, W., Liu, Y., & Su, W. (2022) · PubMed Central · Cited by 32
Self-citationBondarev, A. D., Jonsson, J., Chubarev, V. N., Tarasov, V. V., Lagunas‐Rangel, F. A., & Schiöth, H. B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107431 · Cited by 34
Leyton, J. V. (2020) · Antibodies · doi:10.3390/antib9030032 · Cited by 34
An overview of antibody–drug conjugates in oncological practice
Theocharopoulos, C., Lialios, P., Gogas, H. J., & Ziogas, D. C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920962997 · Cited by 32
Yang, J., Han, J., Zhang, Y., Muhetaer, M., Chen, N., & Yan, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924126 · Cited by 32
An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs
Gandullo‐Sánchez, L., & Pandiella, A. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216024 · Cited by 32
Boch, T., Köhler, J., Janning, M., & Loges, S. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0540 · Cited by 32
Yang, C., Zhang, X., Chen, Y., Li, P., Zhang, J., Xu, A., Huang, N., Liang, M., Chen, Y., & Wang, K. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103962 · Cited by 32
Antibody-drug conjugates for urothelial carcinoma
Thomas, J., Sun, M., Getz, T. M., Ho, B., Nauseef, J. T., & Tagawa, S. T. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.06.006 · Cited by 35
Kaneko, M. K., Suzuki, H., Ohishi, T., Tanaka, T., & Kato, Y. (2024) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2023.0033 · Cited by 32
Yamashita, T., Sohn, J., Tokunaga, E., Niikura, N., Park, Y. H., Lee, K. S., Chae, Y. S., Xu, B., Wang, X., Im, S., et al. (2024) · Breast Cancer · doi:10.1007/s12282-024-01600-7 · Cited by 31
Self-citationManagement of ER positive metastatic breast cancer
McAndrew, N. P., & Finn, R. S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.005 · Cited by 33
Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
Kotani, D., & Shitara, K. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920986518 · Cited by 31
Huang, Y.-H., Chu, P., Chen, J., Huang, C., Huang, C.-C., Tsai, Y., Wang, Y.-L., Lien, P., Tseng, L., & Liu, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-91588-3 · Cited by 31
Page, D. B., Beal, K. P., Linch, S. N., Spinelli, K. J., Rodine, M., Halpenny, D. F., Modi, S., Patil, S. N., Young, R. J., Kaley, T. J., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00404-2 · Cited by 33
Self-citationTargeting the complexity of ERBB2 biology in gastroesophageal carcinoma
Augustin, J., Soussan, P., & Bass, A. J. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.001 · Cited by 33
Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2
Schlam, I. M., Moges, R., Morganti, S., Tolaney, S. M., & Tarantino, P. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104090 · Cited by 30
Baba, T., Kusumoto, M., Kato, T., Kurihara, Y., Sasaki, S., Oikado, K., Saito, Y., Endo, M., Fujiwara, Y., Kenmotsu, H., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02414-x · Cited by 30
Liu, F., Yin, G., Xue, S., Rehman, F. U., Liao, D., & Pan, Y. (2023) · Journal of Cancer · doi:10.7150/jca.86746 · Cited by 30
Koganemaru, S., Fuchigami, H., Morizono, C., Shinohara, H., Kuboki, Y., Furuuchi, K., Uenaka, T., Doi, T., & Yasunaga, M. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0267 · Cited by 33
Signaling pathway dysregulation in breast cancer
Ryspayeva, D., Seyhan, A. A., MacDonald, W., Purcell, C., Roady, T. J., Ghandali, M., Verovkina, N., El‐Deiry, W. S., Taylor, M. S., & Graff, S. L. (2025) · Oncotarget · doi:10.18632/oncotarget.28701 · Cited by 31
Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis
Routman, D. M., Chera, B. S., & Gupta, G. P. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000437 · Cited by 30
The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
Stravodimou, A., & Voutsadakis, I. A. (2020) · Anticancer Research · doi:10.21873/anticanres.14486 · Cited by 30
Bianchini, G., Arpino, G., Biganzoli, L., Lonardi, S., Puglisi, F., Santini, D., Lambertini, M., & Pappagallo, G. L. (2022) · Cancers · doi:10.3390/cancers14041022 · Cited by 30
Koster, K., Huober, J., & Joerger, M. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00069 · Cited by 30
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer
Ganguly, S., & Gogia, A. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_84_22 · Cited by 30
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 30
Dong, Z., Huang, Z., Li, S., Wang, Y., Yao, Y., Yang, X., & Xu, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.021 · Cited by 30
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
Jiang, T., Su, H., Xu, J., Li, C., Zhang, N., Li, Y., Wu, Y., Ni, R., Ming, Y., Li, Z., et al. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986231224227 · Cited by 30
Morrison, L., & Okines, A. F. C. (2023) · Cancers · doi:10.3390/cancers15153801 · Cited by 29
Villacampa, G. J., Morgado, P. C., Carità, L., Navarro, V., Pascual, T., & Dienstmann, R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102847 · Cited by 31
Liao, D., Zhang, J., Yan, T., Chen, Y., Fu, Y., Xie, N., & Long, M. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s508773 · Cited by 30
Cancer metastasis: molecular mechanisms and therapeutic interventions
Dai, X., Xi, M., & Li, J. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00261-y · Cited by 29
Lv, Y., Cui, X., Li, T., Liu, C., Wang, A., Wang, T., Zhou, X., Li, R., Zhang, F., Hu, Y., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01655-6 · Cited by 29
Research advances and new challenges in overcoming triple-negative breast cancer
Zong, Y., & Pegram, M. D. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.04 · Cited by 29
Angeli, E., & Bousquet, G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091446 · Cited by 30
Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
Prados‐Carvajal, R., Irving, E., Lukashchuk, N., & Forment, J. V. (2021) · Cancers · doi:10.3390/cancers14010044 · Cited by 31
Refining the definition of HER2 ‐low class in invasive breast cancer
Atallah, N. M., Toss, M. S., Green, A. R., Mongan, N. P., Ball, G., & Rakha, E. A. (2022) · Histopathology · doi:10.1111/his.14780 · Cited by 29
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Brasó‐Maristany, F., Griguolo, G., Chic, N., Pascual, T., Paré, L., Maués, J., Galván, P., Dieci, M. V., Miglietta, F., Giarratano, T., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac227 · Cited by 29
Antonarelli, G., Corti, C., Tarantino, P., Salimbeni, B. T., Zagami, P., Marra, A., Trapani, D., Tolaney, S. M., Cortés, J., & Curigliano, G. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101608 · Cited by 29
Hingorani, P., Zhang, W., Zhang, Z., Xu, Z., Wang, W.-L., Roth, M. E., Wang, Y., Gill, J. B., Harrison, D. J., Teicher, B. A., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0758 · Cited by 28
Sevieri, M., Mazzucchelli, S., Barbieri, L., Garbujo, S., Carelli, S., Bonizzi, A., Rey, F., Recordati, C., Recchia, M., Allevi, R., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106934 · Cited by 28
Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index
Gong, J., Zhang, W., & Balthasar, J. P. (2025) · Cancers · doi:10.3390/cancers17061032 · Cited by 28
Zhang, T., Xu, J., Yin, J., Gao, Y., Zheng, H., Fu, B., Sun, J., Xu, Z., Tu, S., Mao, Y., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326691 · Cited by 30
Salting the Soil: Targeting the Microenvironment of Brain Metastases
Srinivasan, E. S., Tan, A. C., Anders, C. K., Pendergast, A. M., Sipkins, D. A., Ashley, D. M., Fecci, P. E., & Khasraw, M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0579 · Cited by 29
A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer
Nguyen, X., Hooper, M., Borlagdan, J., & Palumbo, A. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028021998320 · Cited by 28
Developing Precision Medicine for Bladder Cancer
Guercio, B. J., Iyer, G., & Rosenberg, J. E. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.02.008 · Cited by 30
Simmons, C. E., Rayson, D., Joy, A. A., Henning, J., Lemieux, J., McArthur, H. L., Card, P. B., Dent, R. A., & Brezden‐Masley, C. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211066677 · Cited by 29
Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
Zhang, X., Huang, A. C., Chen, F., Chen, H., Li, L., Kong, N., Luo, W., & Fang, J. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac001 · Cited by 28
Clinical trial data and emerging strategies: HER2-positive breast cancer
Pernas, S., & Tolaney, S. M. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06575-7 · Cited by 28
Ramamoorthi, G., Kodumudi, K. N., Snyder, C., Grover, P., Zhang, H., Greene, M. I., Basu, A. B., Gallen, C., Wiener, D. A., Costa, R. L. B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004841 · Cited by 28
Therapeutic landscape of advanced HER2-positive breast cancer in 2022
Gupta, R., Gupta, S., Antonios, B., Ghimire, B., Jindal, V., Deol, J., Gaikazian, S., Huben, M. T., Anderson, J., Stender, M., et al. (2022) · Medical Oncology · doi:10.1007/s12032-022-01849-y · Cited by 30
Xu, B., Li, W., Zhang, Q., Li, Q., Wang, X., Li, H., Sun, T., Yin, Y., Zheng, H. Y., Feng, J., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06775-1 · Cited by 30
Precision targeted therapy for EGFR mutation‐positive NSCLC : Dilemmas and coping strategies
Meng, Y., Bai, R., & Cui, J. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14858 · Cited by 28
Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
Subhan, M. A., & Torchilin, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041242 · Cited by 28
Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation
Oikawa, M., Ishida, T., & Takeishi, Y. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.04.006 · Cited by 27
Immunotherapy for HER-2 positive breast cancer
Yang, T., Kang, L., Li, D., & Song, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1097983 · Cited by 29
Tolaney, S. M., Goel, S., Nadal, J. C., Denys, H. G., Borrego, M. R., Litchfield, L. M., Liu, J., Appiah, A. K., Chen, Y., & André, F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1209 · Cited by 28
Dowling, G. P., Toomey, S., Bredin, P., Parker, I., Mulroe, E., Marron, J., McLoughlin, O., Teiserskiene, A., Power, C. P., O’Shea, A. M., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11851-4 · Cited by 27
Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs)
Lindgren, E. S., Yan, R., Çil, O., Verkman, A. S., Chan, M. F., Seitzman, G. D., Farooq, A. V., Huppert, L. A., Rugo, H. S., Pohlmann, P. R., et al. (2024) · Current Ophthalmology Reports · doi:10.1007/s40135-024-00322-5 · Cited by 28
Iwata, H., Xu, B., Kim, S., Chung, W., Park, Y. H., Kim, M. H., Tseng, L., Chung, C.-F., Huang, C., Kim, J. H., et al. (2024) · Cancer Science · doi:10.1111/cas.16234 · Cited by 27
Self-citationLin, S., Zhang, Y. L., Yao, J., Yang, J., Qiu, Y., Zhu, Z., & Hua, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05568-y · Cited by 27
Breast cancer and cardiovascular health
López‐Fernández, T., Clement, I. M., Aznar, M. C., Barac, A., Bergler-Klein, J. K., Meattini, I., Scott, J. M., Cardinale, D. M., & Dent, S. F. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae637 · Cited by 31
The Evolving Landscape of HER2-Directed Breast Cancer Therapy
Marti, J. L. G., Hyder, T., Nasrazadani, A., & Brufsky, A. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00780-6 · Cited by 28
Kearney, M., Franks, L. E., Lee, S. Y., Tiersten, A., Makower, D., Cigler, T., Mundi, P. S., Chi, D.-C., Goel, A., Klein, P., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06306-4 · Cited by 27
Metadata
- Authors
- Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., Sohn, J., Denduluri, N., Perrin, C., Aogi, K., Tokunaga, E., Im, S.-A., Lee, K. S., Hurvitz, S. A., Cortes, J., Lee, C., Chen, S., Zhang, L., Shahidi, J., Yver, A., & Krop, I.
- Affiliations
- SHOWA Medical University (JP)
- From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 610-621
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7458671
- OpenAlex
- W2996630100
- Cited by
- 2,006
- References
- 40
- Citations by year
- 2026: 234 · 2025: 266 · 2024: 317 · 2023: 355 · 2022: 345 · 2021: 312 · 2020: 174
- FWCI
- 86.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- trastuzumab deruxtecan, HER2-positive breast cancer, metastatic breast cancer, trastuzumab emtansine, antibody-drug conjugates, previously treated patients, objective response rate, progression-free survival, neutropenia, dose escalation, topoisomerase I inhibitor, HER2-targeted therapy, treatment efficacy and safety
- MeSH terms
- Trastuzumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Female, Humans, Middle Aged, Lung Diseases, Interstitial, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Kaplan-Meier Estimate, Intention to Treat Analysis, Consolidation Chemotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
